NCT06738745View on ClinicalTrials.gov

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

August 31, 2027

Conditions

Prostate Cancer Metastatic Disease

Interventions

DRUG

HRS-2189

HRS-2189

DRUG

HRS-5041

HRS-5041

Trial Locations (1)

200230

Fudan Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER